In the first part of a two part webinar series, we take the opportunity to interact with the CEO of Oramed Pharmaceuticals Inc., Mr Nadav Kidron to discover, understand and unravel the journey of OralInsulin - from concept to a successful phase 3 candidate. Throughout history, oral administration has been regarded as the most convenient mode of drug delivery, as it requires minimal expertise and invasiveness. Although oral delivery works well for small-molecule drugs, oral delivery of macromolecules (particularly proteins and peptides) has been limited by acidic conditions in the stomach and low permeability across the intestinal epithelium. Oramed, is one one such company, that has made tremendous strides in the oral delivery of proteins and peptides, beginning with oral delivery of insulin (ORMD-0801) at Phase 3 entry in US.
01 November 2020
